Erratum: A practical synthesis of renin inhibitor MK-1597 (ACT-178882) via catalytic enantioselective hydrogenation and epimerization of piperidine intermediate (Journal of Organic Chemistry (2011) 76 (1062-1071) DOI: 10.1021/jo102070e);A practical synthesis of renin inhibitor MK-1597 (ACT-178882) via catalytic enantioselective hydrogenation and epimerization of piperidine intermediate

Journal of Organic Chemistry

Volumn 76, Issue 4, 2011, Pages 1062-1071

  Molinaro, Carmela ^a   Shultz, Scott ^b   Roy, Amélie ^a   Lau, Stephen ^a   Trinh, Thao ^a   Angelaud, Rémy ^a   O'Shea, Paul D ^a   Abele, Stefan ^c   Cameron, Mark ^b   Corley, Ed ^b   Funel, Jacques Alexis ^c   Steinhuebel, Dietrich ^b   Weisel, Mark ^b   Krska, Shane ^b  

^a Merck ^*  (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENANTIOSELECTIVITY; HYDROGENATION;

AMINE FRAGMENTS; ASYMMETRIC HYDROGENATION; AVAILABLE P; ENANTIOSELECTIVE HYDROGENATION; ENANTIOSELECTIVE SYNTHESIS; EPIMERIZATION; STEREOCENTERS; SYNTHETIC ROUTES;

SYNTHESIS (CHEMICAL);

6 [2 (2,6 DICHLORO 4 METHYLPHENOXY)ETHOXY] 1',2',3',4',5',6' HEXAHYDRO [3,4']BIPYRIDINYL 3' CARBOXYLIC ACID [2 CHLORO 5 (2 METHOXYETHYL)BENZYL]CYCLOPROPYLAMIDE; ACT 178882; AMINE; ANTIHYPERTENSIVE AGENT; MK 1597; PARA CRESOL; PIPERIDINE DERIVATIVE; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG SYNTHESIS; ENANTIOSELECTIVITY; EPIMERIZATION; HYDROGENATION; HYPERTENSION; SAPONIFICATION; STEREOCHEMISTRY; SUBSTITUTION REACTION;

EID: 79951668329     PISSN: 00223263     EISSN: 15206904     Source Type: Journal    
DOI: 10.1021/jo202488m     Document Type: Erratum

References (48)

1. MacGregor, G. A.; Markandu, N. D.; Roulston, J. E.; Jones, J. C.; Morton, J. J. Nature 1981, 291, 329
2. Weber, M. A. Am. J. Hypertens. 1999, 12, 189S
3. Weir, M. R.; Dzau, V. J. Am. J. Hypertens. 1999, 12, 205S
4. Brewster, U. C.; Perazella, M. A. Am. J. Med. 2004, 116, 263
5. Chen, A.; Bayly, C.; Bezençon, O.; Richard-Bildstein, S.; Dubé, D.; Dubé, L.; Gagné, S.; Gallant, M.; Gaudreault, M.; Grimm, E.; Houle, R.; Lacombe, L.; Laliberté, S.; Lévesque, J.-F.; Liu, S.; MacDonald, D.; Mackay, B.; Martin, D.; McKay, D.; Powell, D.; Remeň, L.; Soisson, S.; Toulmond, S. Bioorg. Med. Chem. Lett. 2010, 20, 2204
6. Patchett, A. A.; Cordes, E. H. Adv. Enzymol. Relat. Areas Mol. Biol. 1985, 57, 1
7. Fyhrquist, F. Drugs 1986, 32 (Suppl. 5) 33
8. Ruilope, L. M.; Rosei, E. A.; Bakris, G. L.; Mancia, G.; Poulter, N. R.; Taddei, S.; Unger, T.; Volpe, M.; Waeber, B.; Zanna, F. Blood Pressure 2005, 14, 196
9. Oparil, S.; Yarows, S. A.; Patel, S.; Fang, H.; Zhang, J.; Satlin, A. Lancet 2007, 370, 221
10. Kasani, A.; Subedi, R.; Stier, M.; Holsworth, D. D.; Maiti, S. N. Heterocycles 2007, 73, 47
11. Fisher, N. D. L.; Hollenberg, N. K. J. Am. Soc. Nephrol. 2005, 16, 592
12. Amin Zaman, M.; Oparil, S.; Calhoun, D. A. Nat. Rev. Drug. Discovery 2002, 1, 621
13. Rahuel, J.; Rasetti, V.; Maibaum, J.; Rueger, H.; Goschke, R.; Cohen, N.-C.; Stutz, S.; Cumin, F.; Fuhrer, W.; Wood, J. M.; Gruetter, M. G. Chem. Biol. 2000, 7, 493
14. Wood, J. M.; Stanton, J. L.; Hofbauer, K. G. J. Enzyme Inhib. 1987, 1, 169
15. Rahuel, J.; Priestle, J. P.; Gruetter, M. G. J. Struct. Biol. 1991, 107, 227
16. Corminboeuf, O.; Bezençon, O.; Grisostomi, C.; Remeň, L.; Richard-Bildstein, S.; Bur, D.; Prade, L.; Hess, P.; Strickner, P.; Fischli, W.; Steiner, B.; Treiber, A. Bioorg. Med. Chem. Lett. 2010, 20, 6286
17. Corminboeuf, O.; Bezençon, O.; Remeň, L.; Grisostomi, C.; Richard-Bildstein, S.; Bur, D.; Prade, L.; Strickner, P.; Hess, P.; Fischli, W.; Steiner, B.; Treiber, A. Bioorg. Med. Chem. Lett. 2010, 20, 6291
18. Also known as ACT-178882.
19. Bouveault, L. Bull. Soc. Chim. Fr. 1904, 31, 1306
20. Bouveault, L. Bull. Soc. Chim. Fr. 1904, 31, 13C22
21. Boymond, L.; Rottlander, M.; Cahiez, G.; Knochel, P. Angew.Chem., Int. Ed. 1998, 37, 1701
22. Abarbri, M.; Dehmel, F.; Knochel, P. Tetrahedron Lett. 1999, 40, 7449
23. Jensen, A. E.; Dohle, W.; Sapountzis, I.; Lindsay, D. M.; Vu, V. A.; Knochel, P. Synthesis 2002, 4, 565
24. Knochel, P.; Dohle, W.; Gommermann, N.; Kneisel, F. F.; Kopp, F.; Korn, T.; Sapountzis, I.; Vu, V. A. Angew. Chem., Int. Ed. 2003, 42, 4302
25. Staudinger, H.; Meyer, J. Helv. Chim. Acta 1919, 2, 635
26. Coffman, D. D.; Marvel, C. S. J. Am. Chem. Soc. 1929, 51, 3496
27. Wittig, G.; Geissler, G. Ann. 1953, 580, 44
28. Wittig, G.; Schollkopf, U. Chem. Ber. 1954, 97, 1318
29. Wittig, G.; Haag, W. Chem. Ber. 1955, 88, 1654
30. Horner, L.; Hoffmann, H. M. R.; Wippel, H. G. Ber. 1958, 91, 61
31. Horner, L.; Hoffmann, H. M. R.; Wippel, H. G.; Klahre, G. Ber. 1959, 92, 2499
32. Wadsworth, W. S., Jr.; Emmons, W. D. J. Am. Chem. Soc. 1961, 83, 1733
33. A% = HPLC area percent monitored at 220 nm.
34. Other Pt-and Rh-based metals were also tested; however, much lower reactivities and/or purity profiles were observed.
35. 3·THF see: Kanth, J. V. B.; Brown, H. C. Inorg. Chem. 2000, 39, 1795 and references therein
36. Ishiyama, T.; Matsuda, N.; Miyaura, N. J. Org. Chem. 1995, 60, 7508
37. Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457
38. Petersen, M. D.; Boye, S. V.; Nielsen, E. H.; Willumsen, J.; Sinning, S.; Wiborg, O.; Bols, M. Bioorg. Med. Chem. 2007, 15, 4159
39. For a description of the microscale screening conditions utilized in this study see: Shultz, C. S.; Krska, S. Acc. Chem. Res. 2007, 40, 1320
40. Previous approaches to this class of intermediates include: (1) racemic hydrogenation followed by HPLC chiral separation: Patane, M. A.; DiPardo, R. M.; Price, R. P.; Chang, R. S. L.; Ransom, R. W.; O'Malley, S. S.; Di Salvo, J.; Bock, M. G. Bioorg. Med. Chem. Lett. 1998, 8, 2495
41. Bachmann, S.; Scalone, M.; Schnider, P. Process for the preparation of enantiomerically enriched cyclic β-aryl or heteroaryl carboxylic acids. U.S. Pat. Appl. 2007/0232653 A1, 2007; (2) resolution of the racemic carboxylic acid: ref 16a; (3) asymmetric hydrogenation on the carboxylic acid: ref 16b.
42. Other ligands tested: (S)-xyl-BINAP, (R, R)-Me-DuPhos, (R, R, S, S)-Tangphos, W006-1, Catasium I, J004-1 and J212-1 (structures are available in the Supporting Information)
43. The Darco treatment is necessary to reduce the metal content in the product. Before treatment the levels are >20000 ppm.
44. Isolation of the product and resubjecting the esters to the same epimerization conditions did not change the trans / cis ratio observed.
45. The rate of dissolution or solubility of different NaOEt sources in ethanol may explain the different results observed.
46. A full mechanism analysis is underway and will be reported in due course.
47. Alternatively 10 equiv of TFA can be used with carefull monitoring of the KF.
48. Gauvreau, D.; Huffman, M. A.; Hughes, G.; Itoh, T.; Yin, J.; Lau, S.; O'Shea, P. Process for the preparation of diazabicyclo[3.3.1]nonane derivatives. WO 2008/088690 A2, 2008.